
1. malar j. 2019 oct 16;18(1):349. doi: 10.1186/s12936-019-2984-7.

k13-propeller gene polymorphisms plasmodium falciparum therapeutic
effect artesunate among migrant workers returning guangxi, china
(2014-2017).

li j(1), shi y(2), zhang w(1), yan h(1), lin k(1), wei s(1), wei h(1), yang y(1),
huang s(3), lu y(3), a(4), qin j(4).

author information: 
(1)institute parasitic disease prevention control, guangxi zhuang
autonomous region center disease control prevention, nanning, 530028,
china.
(2)institute parasitic disease prevention control, guangxi zhuang
autonomous region center disease control prevention, nanning, 530028,
china. syunliang2008@126.com.
(3)the peoples hospital shanglin county, nanning, 530500, china.
(4)shanglin county center disease control prevention, nanning, 530500,
china.

background: resistance plasmodium falciparum artemisinin been
identified asia parts africa. drug resistance p. falciparum
will obstacle successful elimination malaria 2025.
whole-genome sequencing artemisinin-resistant parasite line revealed
mutations k13 gene associated drug resistance p. falciparum. to
understand artemisinin resistance imported p. falciparum cases from
africa, mutations k13 gene parasites imported malaria cases in
guangxi province detected treatment efficiency artesunate
monotherapy observed.
methods: dna extracted 319 blood samples migrant workers p.
falciparum infection returned hometown guangxi province from
africa 2014 2017. k13-propeller gene amplified nested pcr,
and sequencing, gene mutation frequency geographic difference imported p. 
falciparum cases analysed comparison wild-type strain. 319
patients, 158 p. falciparum-infected treated intravenous
injection artesunate observed, including time asexual stage
clearance dose artesunate used.
results: 319 p. falciparum samples, 12 samples k13-propeller
mutation, 11 point mutations detected; 5 non-synonymous mutations
(t474i, a481t, a578s, v603e, g665s) associated artemisinin
resistance. clinical treatment observation showed median (iqr) dose 
of artesunate peripheral blood parasite asexual stage clearance 407.55
(360-510) mg, d3 parasite clearance rate 70.25%, including five
k13-propeller mutations p. falciparum. 7 days treatment, 98.73% of
cases cleared. two cases treated artemisinin 8 days a
960-mg dose completely clear asexual parasite, a
mutation k13 gene.
conclusions: five mutations k13-propeller gene 319 p. falciparum
samples patients returning africa identified. frequency the
k13-propeller mutants low, mutations strongly associated
with artemisinin resistance. median (iqr) dose artesunate monotherapy in
actual clinical treatment remove asexual parasite stages 407.55 (360-510) 
mg, equivalent d3-d4. p. falciparum cases without k13-propeller
mutation showed obvious delayed clearance parasite peripheral blood. 
trial registration diagnosis malaria treatment malaria-infected
patients routine work centres disease control prevention.
information patients conveyed patient's approval, the
research aim, methods, risks benefits study explained detail
to patients.

doi: 10.1186/s12936-019-2984-7 
pmcid: pmc6794752
pmid: 31619243  [indexed medline]

